Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The total therapy (TT) IIIB phase 2 study incorporated bortezomib into tandem melphalan–based hematopoietic stem cell transplantation with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide for induction/consolidation and bortezomib, lenalidomide, and dexamethasone (VRD) for maintenance in patients with newly diagnosed multiple myeloma (MM). This updated analysis presents a 15.4-year median follow-up. Of 177 patients, 21% patients had gene expression profile (GEP)–defined high-risk MM. 15-year progression free survival (PFS) was 27.9%. Median PFS was better in GEP–defined low-risk patients at 7.8 years and in International Staging System stage 1 patients at 8.7 years. Overall, median OS was 9.1 years, and 15-year overall survival (OS) was 35.9%. GEP–defined low-risk patients’ median OS was 11.2 years, and that of GEP–defined high-risk patients was 2.8 years. There was no difference in OS between TT IIIB and TT IIIA. This study includes the longest follow-up of patients treated with maintenance VRD reported to date. In patients with GEP–defined low-risk, nearly half and one-third of patients without ongoing treatment showed no signs of progression at 10 and 15 years, respectively. One-third of patients survived more than 15 years, but 3 years of VRD maintenance did not improve outcomes for patients with GEP–defined high-risk MM.

Figures

References Powered by Scopus

The molecular classification of multiple myeloma

960Citations
N/AReaders
Get full text

Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

802Citations
N/AReaders
Get full text

Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis

527Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies

4Citations
N/AReaders
Get full text

Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma

0Citations
N/AReaders
Get full text

Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Al Hadidi, S., Ababneh, O. E., Schinke, C. D., Thanendrarajan, S., Bailey, C., Smith, R., … van Rhee, F. (2024). Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Advances, 8(3), 703–707. https://doi.org/10.1182/bloodadvances.2023011601

Readers over time

‘23‘24‘2502468

Readers' Seniority

Tooltip

Professor / Associate Prof. 2

50%

PhD / Post grad / Masters / Doc 2

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

100%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 41

Save time finding and organizing research with Mendeley

Sign up for free
0